Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | CCR6 | P51684 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL27943068 | 0.83 | ESR1 (0.44) | ALDH1A1LMNASMN1; SMN2TSHRHPGD | |
| SCHEMBL6694454 | 0.82 | ALDH1A1 (0.39) | ALDH1A1LMNAALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL4352238 | 0.78 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3263644 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL7736055 | 0.78 | ALDH1A1 (0.42) | ALDH1A1LMNAALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL9750201 | 0.78 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9820028 | 0.76 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5606415 | 0.75 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2TSHRHPGDMEN1 | |
| Hydrochloric Acid SCHEMBL9062504 | 0.73 | GAA (0.35) | ALDH1A1LMNAALOX15HSD17B10HPGD | |
| SCHEMBL5461842 | 0.73 | ALDH1A1 (0.33) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3064199-B1 | ABUSE-DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | BUZZZ PHARMACEUTICALS LTD (IE) | 2023-12-20 | — | — | EP | claimed |
| US-20150197484-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | US | claimed |
| WO-2012148550-A1 | PRODRUGS OF THERAPEUTIC COMPOUNDS | MYREXIS, INC. (US) | 2012-11-01 | — | — | WO | claimed |
| EP-2473475-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | AllTranz Inc. (US) | 2012-07-11 | — | — | EP | claimed |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | US | claimed |
| WO-2011026144-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | WO | claimed |
| EP-2176208-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | AllTranz Inc. (US) | 2010-04-21 | — | — | EP | claimed |
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | US | claimed |
| WO-2009018389-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | WO | claimed |
| EP-1392718-B1 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | GENEPROT INC (CH) | 2006-01-11 | — | — | EP | claimed |
| US-20050064538-A1 | Native chemical ligation with three or more components | ASTRAZENECA PHARMACEUTICALS LP | 2005-03-24 | — | — | US | claimed |
| EP-1392718-A2 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | Geneprot, Inc. (CH) | 2004-03-03 | — | — | EP | claimed |
| WO-2002098902-A2 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | GENEPROT, INC. (CH) | 2002-12-12 | — | — | WO | claimed |
| US-11873272-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | Niche Biopharmaceuticals LLC (US) | 2024-01-16 | — | — | US | disclosed |
| EP-3064199-B1 | ABUSE-DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | BUZZZ PHARMACEUTICALS LTD (IE) | 2023-12-20 | — | — | EP | disclosed |
| EP-4214191-A1 | ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES | Niche Biopharmaceuticals LLC (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-1392718-B1 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | GENEPROT INC (CH) | 2006-01-11 | — | — | EP | disclosed |
| US-20050064538-A1 | Native chemical ligation with three or more components | ASTRAZENECA PHARMACEUTICALS LP | 2005-03-24 | — | — | US | disclosed |
| EP-1392718-A2 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | Geneprot, Inc. (CH) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098902-A2 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | GENEPROT, INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 1490/4885LMNA 1353/4885ALOX15 388/4885 |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | PNLIP, CNR2, CNR1 | ALDH1A1 3684/4885LMNA 3547/4885ALOX15 516/4885 |
| US-20050064538-A1 | Native chemical ligation with three or more components | VIP, PTMS, FGB | ALDH1A1 2856/4885LMNA 2989/4885ALOX15 4204/4885 |
| US-11873272-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | MAVS, SARS1, MGLL | ALDH1A1 3686/4885LMNA 4761/4885ALOX15 2289/4885 |
| US-20150197484-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | PNLIP, CNR2, CNR1 | ALDH1A1 3684/4885LMNA 3547/4885ALOX15 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.